• info@heparegenix.com
  • +49 (0)7071 7912810
  • Sitemap
  • Site Notice
  • Privacy Policy
HepaRegeniX GmbH
  • Home
  • About us
  • Investors
  • Science
  • Jobs
  • Press
  • Contact
Search
  • Home
  • About us
  • Investors
  • Science
  • Jobs
  • Press
  • Contact

HepaRegeniX GmbH achieves successful proof of efficacy in acute liver disease models for selected MKK4 inhibitors

p3889712020-07-07T08:13:45+02:00

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...

7. July 2020
By p388971Press releaseComments Off
Read more...

HepaRegeniX GmbH zeigt Wirksamkeit ausgewählter MKK4-Inhibitoren in verschiedenen Modellen zu akuten Lebererkrankungen

p3889712020-07-07T11:20:22+02:00

Präklinische Daten zeigen die Wirksamkeit von MKK4-Inhibitoren im Bereich der Leberregeneration sowie experimentellen Modellen aktuer und chronischer Lebererkrankungen...

7. July 2020
By p388971PressemitteilungComments Off
Read more...

HepaRegeniX GmbH secures Series B Financing in excess of € 11 Mio. to advance first drug candidate to the clinic

p3889712020-05-28T10:48:34+02:00

Preclinical data demonstrate efficacy of MKK4 inhibitors in liver regeneration and experimental acute and chronic liver disease models...

21. January 2020
By p388971Press releaseComments Off
Read more...

HepaRegeniX GmbH schließt eine Finanzierungsrunde über € 11 Mio. ab zum Start der klinischen Prüfung des ersten Medikamentenkandidaten

p3889712020-06-08T11:22:52+02:00

Präklinische Daten zeigen die Wirksamkeit von MKK4-Inhibitoren im Bereich der Leberregeneration sowie experimentellen Modellen aktuer und chronischer Lebererkrankungen...

21. January 2020
By p388971PressemitteilungComments Off
Read more...

HepaRegeniX GmbH announces management changes: Dr. Michael Lutz appointed as new CEO/Managing Director

p3889712020-03-20T08:49:47+01:00

Dr. Lutz is an experienced biotech entrepreneur who has spent the last 15 years at executive management positions with several Life Sciences companies...

17. October 2019
By p388971Press releaseComments Off
Read more...

HepaRegeniX GmbH kündigt Management-Wechsel an: Dr. Michael Lutz zum neuen CEO/Geschäftsführer benannt

p3889712020-06-08T11:24:41+02:00

Dr. Lutz is an experienced biotech entrepreneur who has spent the last 15 years at executive management positions with several Life Sciences companies which he successfully established...

17. October 2019
By p388971PressemitteilungComments Off
Read more...

HepaRegeniX GmbH erhält € 9 Mio. in Serie-A Finanzierungsrunde für die Entwicklung von Kinaseinhibitoren zur Behandlung akuter und chronischer Lebererkrankungen

p3889712020-06-08T11:25:02+02:00

HepaRegeniX entwickelt ein neues und einzigartiges therapeutisches Konzept zur Behandlung von Lebererkrankungen, basierend auf einer Entdeckung von Prof. Lars Zender und seiner Forschungsgruppe...

5. January 2017
By p388971PressemitteilungComments Off
Read more...

HepaRegeniX GmbH Raises € 9 million in a Series A Financing to Develop Kinase Inhibitors for the Treatment of Acute and Chronic Liver Diseases

p3889712020-06-08T11:25:21+02:00

HepaRegeniX develops a new and unique therapeutic concept for the treatment of liver diseases, discovered by Prof. Lars Zender and his research group...

5. January 2017
By p388971Press releaseComments Off
Read more...
Get In Touch

HepaRegeniX has successfully discovered and developed several preclinical drug candidates for the treatment of acute and chronic liver diseases.

Get in touch

Phone: +49 (0)7071 7912810
Fax: +49 (0)7071 7912809
E-mail: info@heparegenix.com

Address

HepaRegeniX GmbH
Eisenbahnstraße 63
72072 Tübingen
Germany

© Copyright 2016-2020 HepaRegeniX GmbH. All Rights Reserved.